The Food and Drug Administration (FDA) has approved the sale of a traditional Chinese medicine (TCM) drug used in the mainland for COVID-19 cases.
The Chinese Embassy in Manila hailed the FDA’s approval of the Lianhua Qingwen capsule Wednesday (August 8) as “an important progress in the entry of TCM products into the Philippine market.”
“It is our sincere hope that its entrance into the Philippine market will contribute to the fight against the spread of COVID-19 in this country and help the patients with mild and moderate symptoms recover,” the embassy said.
According to the Chinese embassy, the capsule has been approved by regulators in Hong Kong and Macao SAR of China, Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore and Laos PDR.
The capsule supposedly eases symptoms of COVID-19 such as fever, aversion to cold, muscle soreness and runny nose.
The Chinese embassy advised consumers to buy and consume only authentic TCM products from qualified manufacturers.
The capsule is manufactured by Shijiazhuang Yiling Pharmaceutical Co. Ltd. From Hebei province in China. The local distributor is Philippine Archipelago International Trading Corp. in Balintawak, Quezon City.
Lianhua Qingwen Capsule has been registered in accordance with the
standards for Traditionally-Used Herbal Product in the #Philippines:
Chinese Embassy spokesperson https://t.co/mNQ8esaw0n pic.twitter.com/rtpzSEH519
ChineseEmbassyManila (@Chinaembmanila) August